Subject    :    [2017 Apr;41(2)] Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial
Writer KDA
Date 2017-07-06 11:02:30 Hit 8,371
Diabetes Metab J. 2017 Apr;41(2):135-145. English.
Published online Jan 11, 2017.  https://doi.org/10.4093/dmj.2017.41.2.135 
Copyright © 2017 Korean Diabetes Association
   
Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial
Kyung-Wan Min,1 Bon Jeong Ku,2 Ji-Hyun Lee,3 Min-Seon Kim,4 Kyu-Jeung Ahn,5 Moon-Kyu Lee,6 Satoshi Kokubo,7 Satoshi Yoshida,7 Hyun-Ji Cho,8 and Bong-Soo Cha9
1Department of Internal Medicine, Eulji General Hospital, Eulji University School of Medicine, Seoul, Korea.
2Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
3Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea.
4Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea.
5Department of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong, Kyung Hee University Medical Center, Seoul, Korea.
6Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
7Astellas Pharma Inc., Tokyo, Japan.
8Astellas Korea Inc., Seoul, Korea.
9Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Corresponding author: Bong-Soo Cha. Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. Email: bscha@yuhs.ac 
 
Received August 01, 2016; Accepted October 25, 2016.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

 
Abstract

Background

This is a subgroup analysis of Korean patients from a phase 3 clinical trial investigating the efficacy and safety of ipragliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin.

Methods

This multicenter, placebo-controlled, double-blind, parallel-group study was carried out between November 2011 and January 2013. Patients entered a 2-week placebo pretreatment period, followed by a 24-week treatment period with either ipragliflozin (50 mg/day) or placebo, while continuing metformin. Efficacy outcomes (glycosylated hemoglobin [HbA1c], fasting plasma glucose [FPG], and body weight) and safety outcomes (treatment-emergent adverse events [TEAEs]) were measured and compared between the two treatment groups for patients enrolled in all 18 study sites in Korea.

Results

Eighty-two Korean patients received ipragliflozin (n=43) or placebo (n=39) during the study period. Mean changes in HbA1c levels from baseline to the end of treatment were –0.97% in the ipragliflozin group and –0.31% in the placebo group, with an adjusted between-group difference of –0.60% (P P

Conclusion

Ipragliflozin treatment in addition to metformin led to significant improvement in glycemic outcomes and reduction in body weight in Korean patients with type 2 diabetes mellitus, compared with metformin treatment alone; the safety profile was comparable in both groups.

   
Keywords:
Asia; Diabetes mellitus, type 2; Ipragliflozin; Korea; Metformin; Randomized controlled trial; Sodium-glucose cotransporter 2 inhibitor

Articles - Reviews in DMJ
No. Subject Date Hit ↑
Notice : [2019 June;43(3)] Mitochondrial Dysfunction in Adipocytes as a Primary Cause of Adipose Tissue Inflammation [2019 June;43(3)] Mitochondrial Dysfunction in Adipocytes as a Prima... 2019-06-18 58
Notice : [2019 Apr;43(2)] Associations between Breastfeeding and Type 2 Diabetes Mellitus and Glycemic Control in Parous Women: A Nationwide, Population-Based Study [2019 Apr;43(2)] Associations between Breastfeeding and Type 2 Diabe... 2019-04-18 1,137
Notice : [2019 Apr;43(2)] Increased Nociceptive Responses in Streptozotocin-Induced Diabetic Rats and the Related Expression of Spinal NR2B Subunit of N-Methyl-D-Aspartate Receptors [2019 Apr;43(2)] Increased Nociceptive Responses in Streptozotocin-I... 2019-04-18 871
Notice : [2019 Apr;43(2)] The Risk of Myocardial Infarction and Ischemic Stroke According to Waist Circumference in 21,749,261 Korean Adults: A Nationwide Population-Based Study [2019 Apr;43(2)] The Risk of Myocardial Infarction and Ischemic Stro... 2019-04-18 890
Notice : [2019 Apr;43(2)] Myricetin Protects Against High Glucose-Induced β-Cell Apoptosis by Attenuating Endoplasmic Reticulum Stress via Inactivation of Cyclin-Dependent Kinase 5 [2019 Apr;43(2)] Myricetin Protects Against High Glucose-Induced ... 2019-04-18 840
Notice : [2019 Apr;43(2)] Association between Changes in Anthropometric Indices and in Fasting Insulin Levels among Healthy Korean Adolescents: The JS High School Study [2019 Apr;43(2)] Association between Changes in Anthropometric Indic... 2019-04-18 853
Notice : [2019 Apr;43(2)] Discrepancies between Glycosylated Hemoglobin and Fasting Plasma Glucose for Diagnosing Impaired Fasting Glucose and Diabetes Mellitus in Korean Youth and Young Adults [2019 Apr;43(2)] Discrepancies between Glycosylated Hemoglobin and F... 2019-04-18 876
Notice : [2019 Apr;43(2)] Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors [2019 Apr;43(2)] Predictors of the Therapeutic Efficacy and Consider... 2019-04-18 846
Notice : [2019 Apr;43(2)] Metabolic Consequences of Obstructive Sleep Apnea Especially Pertaining to Diabetes Mellitus and Insulin Sensitivity [2019 Apr;43(2)] Metabolic Consequences of Obstructive Sleep Apnea E... 2019-04-18 852
Notice : [2019 Apr;43(2)] Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment [2019 Apr;43(2)] Nonalcoholic Fatty Liver Disease and Diabetes: Part... 2019-04-18 857
283 [2017 Jun;41(3)] The Effect of 12 Weeks Aerobic, Resistance, and Com... 2017-07-06 9,021
282 [2017 Jun;41(3)] Satisfaction Survey on Information Technology-Based... 2017-07-06 8,939
281 [2017 Jun;41(3)] Impact of Gender on the Association between Low Ser... 2017-07-06 8,719
280 [2017 Jun;41(3)] Comparison of Antidiabetic Regimens in Patients wit... 2017-07-06 8,523
279 [2017 Jun;41(3)] Physician-Directed Diabetes Education without a Med... 2017-07-06 8,420
278 [2017 Apr;41(2)] Association between Blood Mercury Level and Viscera... 2017-07-06 8,390
277 [2017 Apr;41(2)] Addition of Ipragliflozin to Metformin Treatment in... 2017-07-06 8,371
276 [2017 Apr;41(2)] Diabetes Camp as Continuing Education for Diabetes ... 2017-07-06 8,343
275 [2017 Apr;41(2)] Role of NO/VASP Signaling Pathway against Obesity-R... 2017-07-06 8,332
274 [2017 Jun;41(3)] Diabetes Prevention in Australia: 10 Years Results ... 2017-07-06 8,301

목록

Gets the previous 5 pages.   Go to previous page.  [1]   2   3   4   5     Go to next page. Gets the next  5 pages.